Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-7257da0dd1f9dbf780b362b25cce238a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-7257da0dd1f9dbf780b362b25cce238a",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-7257da0dd1f9dbf780b362b25cce238a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-7257da0dd1f9dbf780b362b25cce238a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-7257da0dd1f9dbf780b362b25cce238a</b></p><a name=\"composition-en-7257da0dd1f9dbf780b362b25cce238a\"> </a><a name=\"hccomposition-en-7257da0dd1f9dbf780b362b25cce238a\"> </a><a name=\"composition-en-7257da0dd1f9dbf780b362b25cce238a-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1199/001 72 film-coated tablets</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - cuprior</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/17/1199/001 72 film-coated tablets"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp7257da0dd1f9dbf780b362b25cce238a"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - cuprior",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Cuprior is and what it is used for</li><li>What you need to know before you take Cuprior</li><li>How to take Cuprior</li><li>Possible side effects</li><li>How to store Cuprior</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What cuprior is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What cuprior is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Cuprior is a medicine used to treat Wilson s disease that contains the active substance trientine.</p><p>Wilson s disease is an inherited condition in which the body cannot transport copper around the body in the normal way or remove copper in the normal way as a secretion from the liver into the gut. This means that the small amounts of copper from food and drink build up to excessive levels and can lead to liver damage and problems in the nervous system. This medicine mainly works by attaching to copper in the body which then allows it to be removed in the urine instead, helping to lower copper levels. It may also attach to copper in the gut and so reduce the amount taken up into the body.<br/>Cuprior is given to adults, adolescents and children aged 5 years and over who cannot tolerate another medicine that is used to treat this disease, called penicillamine.</p></div>"
}
},
{
"title" : "2. What you need to know before you take cuprior",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take cuprior"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Cuprior</p><ul><li>if you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking Cuprior.</p><p>If you were already taking another trientine medicine, your doctor may modify your daily dose, the number of tablets or the number of intake in the day when switching to Cuprior treatment.</p><p>Your symptoms may initially get worse after starting the treatment. If this happens, you must tell your doctor.</p><p>Your doctor will regularly check your blood and urine to ensure that you receive the right dose of Cuprior to properly control your symptoms and copper levels.</p><p>You should tell your doctor if you get any side effects as this may indicate that your dose of Cuprior needs to be adjusted up or down.</p><p>This medicine may also reduce the level of iron in your blood and your doctor may prescribe iron supplements (see section Other medicines and Cuprior below).</p><p>If you have kidney problems, your doctor will regularly check that the treatment dose is appropriate and does not affect the functioning of your kidney.</p><p>The association of trientine with another medicine that contains zinc is not recommended.</p><p>Lupus-like reactions (symptoms may include persistent rash, fever, joint pain, and tiredness) have been reported in some patients switched to trientine medicine after penicillamine medicine. However it was not possible to determine if the reaction was due to trientine or to previous penicillamine treatment.</p><p>Children and adolescents Your doctor will carry out checks more frequently to ensure your copper levels are maintained at a suitable level for normal growth and mental development.<br/>This medicine is not recommended for children aged below 5 years of age.</p><p>Other medicines and Cuprior Tell your doctor if you are taking, have recently taken, or might take any other medicines.</p><p>In particular, you must tell your doctor if you are already taking iron supplements or if you take indigestion remedies (medicines that reduce discomfort after eating). If you take these medicines you may need to take Cuprior at a different time in the day because otherwise Cuprior may not be as effective. If you take iron supplements, make sure that at least two hours have passed between taking Cuprior and taking your iron supplements.</p><p>Pregnancy and breast-feeding<br/>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>It is very important to continue treatment to reduce copper during pregnancy. You and your doctor should fully discuss the potential benefits of treatment whilst considering any possible risks that there may be. Your doctor will advise you which treatment and which dose is best in your situation.</p><p>If you are pregnant and taking Cuprior, you will be monitored throughout your pregnancy for any effects on the baby or changes in your copper levels. When your baby is born, the copper level in the baby s blood will also be monitored.</p><p>It is not known if Cuprior can pass into breast milk. It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or to stop taking Cuprior, considering the benefit of breast-feeding to the baby and the benefit of Cuprior to the mother. Your doctor will decide which treatment and which dose is best in your situation.</p><p>Driving and using machines Cuprior is not expected to affect your ability to drive a car or use any tools or machines.</p><p>Cuprior contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium- free.</p></div>"
}
},
{
"title" : "3. How to take cuprior",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take cuprior"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Adults<br/>In adults of all ages, the recommended total daily dose is 3 to 6 and a half tablets per day (making a total of between 450 and 975 mg). This daily total will be divided into 2 to 4 smaller doses to be taken during the day. Your doctor will tell you how many tablets you should take and how often in the day. Tablets can be divided in half if needed.</p><p>Use in children and adolescents (5 to 18 years) The dose that you will take is usually lower than for an adult and depends on your age and body weight.<br/>The usual total daily dose is between 225 and 600 mg (1 and a half to 4 tablets daily), which will be divided into 2 to 4 smaller doses to be taken during the day. Your doctor will tell you how many tablets you should take and how often in the day. Tablets can be divided in half if needed.</p><p>Once you have started the treatment, your doctor may adjust the dose based on the response to treatment.</p><p>Swallow the tablets with water. Take this medicine on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other medicines, food, or milk.</p><p>If you take iron supplements, take them at least two hours after taking a dose of Cuprior.</p><p>If you take more Cuprior than you should Take Cuprior only as it is prescribed for you. If you think you may have taken more Cuprior than you were told to, contact your doctor or pharmacist. If you take more than you should, you may get nausea, vomiting and dizziness.</p><p>If you forget to take Cuprior Do not take a double dose to make up for a forgotten dose. Skip the missed dose and take your next dose at its usual scheduled time.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>If you stop taking Cuprior This medicine is for long-term use. Do not stop your treatment without the advice of your doctor even if you feel better because Wilson s disease is a life-long condition.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects have been reported:</p><p>Common (may affect up to 1 in 10 people)</p><ul><li>feeling sick (nausea)</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>skin rashes</li><li>reddening of the skin (erythema)</li><li>itching</li><li>anaemia</li></ul><p>Not known (frequency cannot be estimated from available data)</p><ul><li>stomach upsets and discomfort, including severe stomach pains (duodenitis)</li><li>inflammation of the gut which may lead to e.g. abdominal pain, recurring diarrhoea and blood in stools (colitis)</li><li>decrease in the number of red blood cells due to low iron level in your blood (iron deficiency)</li><li>urticaria (nettle rash or hives).</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store cuprior",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store cuprior"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Cuprior contains</p><ul><li>The active substance is trientine. Each film-coated tablet contains trientine tetrahydrochloride equivalent to 150 mg trientine.</li><li>The other ingredients are: Tablet core: mannitol, colloidal anhydrous silica and glycerol dibehenate. Tablet film-coating: polyvinyl alcohol, talc, titanium dioxide (E 171), glycerol monocaprylocaprate (Type I), iron oxide yellow (E 172) and sodium laurilsulfate (see section 2 Cuprior contains sodium ).</li></ul><p>What Cuprior looks like and contents of the pack Cupior are yellow, 16 mm x 8 mm oblong film-coated tablets with a score line on each side.<br/>Cuprior is available in blisters containing 72 or 96 film-coated tablets. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>Orphalan 226 Boulevard Voltaire 75011 Paris France</p><p>Manufacturer Delpharm Evreux 5 rue du Guesclin 27000 Evreux France</p><p>This leaflet was last revised in.</p><p>You can find the information also when flashing the QR code below with a smartphone or via the website QR code to be included <a href=\"http://www.cuprior.com\">http://www.cuprior.com</a></p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp7257da0dd1f9dbf780b362b25cce238a",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp7257da0dd1f9dbf780b362b25cce238a",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp7257da0dd1f9dbf780b362b25cce238a\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp7257da0dd1f9dbf780b362b25cce238a</b></p><a name=\"mp7257da0dd1f9dbf780b362b25cce238a\"> </a><a name=\"hcmp7257da0dd1f9dbf780b362b25cce238a\"> </a><a name=\"mp7257da0dd1f9dbf780b362b25cce238a-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1199/001 72 film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Cuprior 150 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/17/1199/001 72 film-coated tablets"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Cuprior 150 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
